NURS 6521 ADVANCED
PHARMACOLOGY EXAM 1 QUESTIONS
AND ANSWERS 100% VERIFIED BY
EXPERTS. 2026/2027
1. A patient with chronic kidney disease requires a medication that is primarily excreted
renally. Which pharmacokinetic parameter is most likely to be affected, necessitating a
dosage adjustment?
A. Half-life
B. Absorption rate
C. Volume of distribution
D. First-pass metabolism
Answer: A
Conceptual Explanation: Renal impairment slows the elimination of drugs, thereby
extending the half-life and increasing the risk of toxicity unless the dose or frequency is
adjusted.
2. When prescribing a drug with a narrow therapeutic index, which of the following actions is
most critical for the Advanced Practice Nurse?
A. Avoid using the drug in geriatric patients altogether
,B. Increase the dose until side effects appear
C. Assume a standard dose for all patients
D. Monitor serum drug levels regularly
Answer: D
Conceptual Explanation: Drugs with a narrow therapeutic index have a small margin
between effective and toxic doses, requiring therapeutic drug monitoring (TDM) to ensure
safety.
3. An 80-year-old patient is prescribed a highly lipophilic medication. How does the
physiological change in body composition associated with aging affect this drug?
A. Decreased volume of distribution
B. Enhanced renal clearance
C. Increased volume of distribution and prolonged half-life
D. Decreased absorption in the small intestine
Answer: C
Conceptual Explanation: Geriatric patients typically have an increased percentage of body
fat, which increases the volume of distribution for lipophilic drugs, leading to a longer half-
life.
4. Which of the following describes a ‘Prodrug’?
A. A drug that is active upon administration but becomes toxic after metabolism
, B. An inactive compound that is converted into an active pharmacological agent by
metabolism
C. A drug that bypasses the liver entirely
D. A drug that binds irreversibly to its receptor
Answer: B
Conceptual Explanation: Prodrugs are pharmacologically inactive when administered and
require metabolic conversion (usually in the liver) to become active.
5. A patient is taking a drug that is a potent inducer of the CYP3A4 enzyme system. If they
start a second drug that is a substrate of CYP3A4, what is the likely outcome?
A. Increased serum levels of the second drug
B. Immediate toxicity of the second drug
C. No change in the metabolism of the second drug
D. Decreased serum levels of the second drug
Answer: D
Conceptual Explanation: Enzyme inducers increase the rate of metabolism of substrate
drugs, which lowers their plasma concentration and potentially reduces therapeutic
efficacy.
6. What is the primary purpose of a ‘loading dose’?
A. To minimize the risk of adverse effects
PHARMACOLOGY EXAM 1 QUESTIONS
AND ANSWERS 100% VERIFIED BY
EXPERTS. 2026/2027
1. A patient with chronic kidney disease requires a medication that is primarily excreted
renally. Which pharmacokinetic parameter is most likely to be affected, necessitating a
dosage adjustment?
A. Half-life
B. Absorption rate
C. Volume of distribution
D. First-pass metabolism
Answer: A
Conceptual Explanation: Renal impairment slows the elimination of drugs, thereby
extending the half-life and increasing the risk of toxicity unless the dose or frequency is
adjusted.
2. When prescribing a drug with a narrow therapeutic index, which of the following actions is
most critical for the Advanced Practice Nurse?
A. Avoid using the drug in geriatric patients altogether
,B. Increase the dose until side effects appear
C. Assume a standard dose for all patients
D. Monitor serum drug levels regularly
Answer: D
Conceptual Explanation: Drugs with a narrow therapeutic index have a small margin
between effective and toxic doses, requiring therapeutic drug monitoring (TDM) to ensure
safety.
3. An 80-year-old patient is prescribed a highly lipophilic medication. How does the
physiological change in body composition associated with aging affect this drug?
A. Decreased volume of distribution
B. Enhanced renal clearance
C. Increased volume of distribution and prolonged half-life
D. Decreased absorption in the small intestine
Answer: C
Conceptual Explanation: Geriatric patients typically have an increased percentage of body
fat, which increases the volume of distribution for lipophilic drugs, leading to a longer half-
life.
4. Which of the following describes a ‘Prodrug’?
A. A drug that is active upon administration but becomes toxic after metabolism
, B. An inactive compound that is converted into an active pharmacological agent by
metabolism
C. A drug that bypasses the liver entirely
D. A drug that binds irreversibly to its receptor
Answer: B
Conceptual Explanation: Prodrugs are pharmacologically inactive when administered and
require metabolic conversion (usually in the liver) to become active.
5. A patient is taking a drug that is a potent inducer of the CYP3A4 enzyme system. If they
start a second drug that is a substrate of CYP3A4, what is the likely outcome?
A. Increased serum levels of the second drug
B. Immediate toxicity of the second drug
C. No change in the metabolism of the second drug
D. Decreased serum levels of the second drug
Answer: D
Conceptual Explanation: Enzyme inducers increase the rate of metabolism of substrate
drugs, which lowers their plasma concentration and potentially reduces therapeutic
efficacy.
6. What is the primary purpose of a ‘loading dose’?
A. To minimize the risk of adverse effects
